The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Kalacheva A.G.

Ivanovo State Medical Academy, Ministry of Health of Russia

Fedotova L.E.

Ivanovo State Medical Academy, Ivanovo

Rudakov K.V.

Ivanovo State Medical Academy, Ivanovo, Russia, Moscow Institute of Physics and Technology, Dolgoprudny, Russia

Molecular mechanisms of pidolate magnesium action and its neurotropic affects

Authors:

Gromova O.A., Torshin I.Iu., Kalacheva A.G., Fedotova L.E., Rudakov K.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(12): 96‑103

DOI: 10.17116/jnevro201611612196-103

Read: 20035 times

Download PDF (RU)
Contact the author
Table of contents

MOLECULAR MECHANISMS OF PIDOLATE MAGNESIUM ACTION AND ITS NEUROTROPIC AFFECTS
MOLECULAR MECHANISMS OF PIDOLATE MAGNESIUM ACTION AND ITS NEUROTROPIC AFFECTS

To cite this article:

Gromova OA, Torshin IIu, Kalacheva AG, Fedotova LE, Rudakov KV. Molecular mechanisms of pidolate magnesium action and its neurotropic affects. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(12):96‑103. (In Russ.)
https://doi.org/10.17116/jnevro201611612196-103

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asso­ciations between sali­vary mine­rals concentrations and caries expe­rience among 12-years old children in Syktyvkar, Komi Repu­blic. Russian Journal of Stomatology. 2025;(2):34-38
Abstract:

Objective. A complex study of pharmacological properties of magnesium pyroglutamate using the modern methods of chemoinformatics and bioinformatics. Material and methods. Pharmacological properties of magnesium pyroglutamate were studied using chemoinformatic and bioinformatic analyses. Results. Neurotropic effects of magnesium pyroglutamate are due to an influence on the synthesis of neuropeptides containing pyroglutamate (orexin, thyroliberin, neurotensin etc) and due to the similarity between pyroglutamate-anion with some neuroactive components (L-theanine, 2-pirrolydinone, piracetam). Conclusion. The results of the study suggest neuroprotective, sedative and antidepressive properties of magnesium pyroglutamate which are realized by pyroglutamate-anion in the synergism with magnesium cation.

Keywords:

magne B6 solution for drinking
pyroglutamate
magnesium
chemoinformatics

Authors:

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Kalacheva A.G.

Ivanovo State Medical Academy, Ministry of Health of Russia

Fedotova L.E.

Ivanovo State Medical Academy, Ivanovo

Rudakov K.V.

Ivanovo State Medical Academy, Ivanovo, Russia, Moscow Institute of Physics and Technology, Dolgoprudny, Russia

Close metadata

References:

  1. Torshin IYu, Gromova OA. Magnesium and pyridoxine: fundamental studies and clinical practice. Nova Science, NY. 2009.
  2. Spravochnik lekarslvennih sredstv. M.: Vidal; 2015. (In Russ.).
  3. Gromova OA, Torshin IYu, Sadin AV, Dsidomorov NYu, Volkov AYu, Grichina TR, Nasarenco OA, Satarina TE, Glagovskii PB, Kalacheva AG, Urgel IS. Dynamics of magnesium concentration in the blood after administration of various drugs magnesium-containing. Farmateka. 2009;10:63-68.
  4. Bikov AT, Andreev AV, Gromova OA. Influence of Magne Вб on cerebrovascular reactivity in children with attention deficit disorder, depending on the content of magnesium in the body. Klinicheskaia farmacologia i terapia. 2000;5:31-34. (in Russ.).
  5. Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol. 2008;140(1):80-85.
  6. Grazzi L, Andrasik F, Usai S, Bussone G. Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up. Neurol Sci. 2007;28(3):148-150.
  7. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res. 2010;23(3):131-137. doi: 10.1684/mrh.2010.0214
  8. Hadjistavri LS, Sarafidis PA, Georgianos PI, Tziolas IM, Aroditis CP, Hitoglou-Makedou A, Zebekakis PE, Pikilidou MI, Lasaridis AN. Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile. Med Sci Monit. 2010;16(6):307-312.
  9. Torshin IYu. Bioinformatics in the post-genomic era: sensing the change from molecular genetics to personalized medicine. Nova Biomedical Books, NY. 2009.
  10. Torshin IYu, Gromova OA. Expertniyu analis dannyh v molecularnoy farmakologii. M.: MCNMO; 2012. (In Russ.).
  11. Dsuravlev YuI, Rudacov КV, Torshin IYu. Algebraic criteria for local solvability and regularity as a tool for studying the morphology of the amino acid sequences. Trudi MFTI. 2011:3:4:67-76. (In Russ.).
  12. Rudakov КV, Torshin IYu. On the selection of informative characteristic values on the basis of criteria for the solvability of the problem of recognition in the protein secondary structure. DAH. 2011;441:1:1-5. (In Russ.).
  13. Torshin IYu, Rudakov KV. On the Application of the Combinatorial Theory of Solvability to the Analysis of Chemographs. Part 1: Fundamentals of Modern Chemical Bonding Theory and the Concept of the Chemograph. Pattern Recognition and Image Analysis. 2014;24:1:11-23.
  14. Torshin IYu, Rudakov KV. On the Application of the Combinatorial Theory of Solvability to the Analysis of Chemographs: Part 2. Local Completeness of Invariants of Chemographs in View of the Combinatorial Theory of Solvability. Pattern Recognition and Image Analysis. 2014;24:2:196-208.
  15. Friesen RW, Novak EM, Hasman D, Innis SM. Relationship of dimethylglycine, choline, and betaine with oxoproline in plasma of pregnant women and their newborn infants. J Nutr. 2007;137(12):2641-2646.
  16. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, Cheng D, Eisner R, Gautam B, Tzur D, Sawhney S, Bamforth F, Greiner R, Li L. The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871(2):164-173. doi: 10.1016/j.jchromb.2008.05.001
  17. Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan WL. Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis. 1993;16(4):648-669.
  18. De Franceschi L, Bachir D, Galacteros F, Tchernia G, Cynober T, Neuberg D, Beuzard Y, Brugnara C. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000;108(2):284-289.
  19. Dusticier N, Kerkerian L, Errami M, Nieoullon A. Effects of pyroglutamic acid on corticostriatal glutamatergic transmission. Neuropharmacology. 1985;24(9):903-908.
  20. Uhlhaas S, Lange H. Striatal deficiency of L-pyroglutamic acid in Huntington's disease is accompanied by increased plasma levels. Brain Res. 1988;457(1):196-199.
  21. Suracova TV, Dsidomorov NYu, Grichina TR, Kodin AA, Chibisov IV, Ularionova EE, Korobova OR, Torshin IYu, Lepahina LE, Gromova OA. Effect of magnesium orotate for skin regeneration. Russkiy medisinskiy zhurnal. 2012;20:575-581. (In Russ.).
  22. Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ. In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol. 2001;116(3):434-442.
  23. Hsu JM, Root AW, Duckett GE, Smith JC Jr, Yunice AA, Kepford G.The effect of magnesium depletion on thyroid function in rats. J Nutr. 1984;114(8):1510-1517.
  24. Vink R, McIntosh TK, Faden AI. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. Brain Res. 1988;460(1):184-188.
  25. El-Etr M, Akwa Y, Baulieu EE, Schumacher M. The neuroactive steroid pregnenolone sulfate stimulates the release of gonadotropin-releasing hormone from GT1-7 hypothalamic neurons, through N-methyl-D-aspartate receptors. Endocrinology. 2006;147(6):2737-2743.
  26. Mahachoklertwattana P, Sanchez J, Kaplan SL, Grumbach MM. N-methyl-D-aspartate (NMDA) receptors mediate the release of gonadotropin-releasing hormone (GnRH) by NMDA in a hypothalamic GnRH neuronal cell line (GT1-1). Endocrinology. 1994;134(3):1023-1030.
  27. Prospero-Garcia O, Mendez-Diaz M. The role of neuropeptides in sleep modulation. Drug News Perspect. 2004;17(8):518-522.
  28. Nakajima C, Kuyama H, Nakazawa T, Nishimura O, Tsunasawa S. A method for N-terminal de novo sequencing of Nalpha-blocked proteins by mass spectrometry. Analyst. 2011;136(1):113-119. doi: 10.1039/c0an00384k
  29. Yamada N, Katsuura G, Tatsuno I, Kawahara S, Ebihara K, Saito Y, Nakao K. Orexins increase mRNA expressions of neurotrophin-3 in rat primary cortical neuron cultures. Neurosci Lett. 2009;450(2):132-135. doi: 10.1016/j.neulet.2008.11.028
  30. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990;247:4949:1446-1451.
  31. Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev. 1999;20(5):599-648.
  32. Lazcano I, Uribe RM, Martinez-Chavez E, Vargas MA, Matziari M, Joseph-Bravo P, Charli JL. Pyroglutamyl peptidase II inhibition enhances the analeptic effect of thyrotropin-releasing hormone in the rat medial septum. J Pharmacol Exp Ther. 2012;342(1):222-231. doi: 10.1124/jpet.112.192278
  33. Li XM, Ferraro L, Tanganelli S, O'Connor WT, Hasselrot U, Ungerstedt U, Fuxe K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J Neural Transm Gen Sect. 1995;102(2):125-137.
  34. Stoessl AJ, Szczutkowski E. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. Brain Res. 1991;558(2):289-295.
  35. Kinkead B, Nemeroff CB. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets. 2006;5(2):205-218.
  36. Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J Pharmacol Exp Ther. 2005;315(1):256-264.
  37. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973;248(19):6854-6861.
  38. Katz LM, Young A, Frank JE, Wang Y, Park K. Neurotensin-induced hypothermia improves neurologic outcome after hypoxic-ischemia. Crit Care Med. 2004;32(3):806-810.
  39. Friry C, Feliciangeli S, Richard F, Kitabgi P, Rovere C. Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity. Biochem Biophys Res Commun. 2002;290(4):1161-1168.
  40. Gendron L, Perron A, Payet MD, Gallo-Payet N, Sarret P, Beaudet A. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. Mol Pharmacol. 2004;66(6):1421-1430.
  41. Vysotskii AL, Vysotskii DL, Gudasheva TA, Ostrovskaya RU, Anokhin KV. Modulation of long-term memory by delayed administration of the amide of L-pyroglutamyl-D-alanine, a nootropic agent, in spaced and massed training in rats. Neurosci Behav Physiol. 1999;29(2):137-142.
  42. Iasnetsov VV, Krylova IN, Provornova NA. Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats. Aviakosm Ekolog Med. 1998;32(1):55-60.
  43. Trofimov SS, Ostrovskaia RU, Smol'nikova NM, Nemova EP, Gudasheva TA, Kuznetsova EA, Voronina TA. The correction with nooglutil and L-pyroglutamyl-D-alanine amide of cognitive disorders in rats due to intrauterine hypoxia. Eksp Klin Farmakol. 1995;58(6):10-13.
  44. Chepkova AN, Doreulee NV, Trofimov SS, Gudasheva TA, Ostrovskaya RU, Skrebitsky VG. Nootropic compound L-pyroglutamyl-D-alanine-amide restores hippocampal long-term potentiation impaired by exposure to ethanol in rats. Neurosci Lett. 1995;188(3):163-166.
  45. Ostrovskaia RU, Gudasheva TA, Trofimov SS, Romanova GA, Dobrynin VP. Behavioral and electrophysiologic characteristics of a peptide analog of piracetam--L-pyroglutamyl-D-alanine amide. Biull Eksp Biol Med. 1987;104(11):576-579.
  46. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004;563(1-3):191-196.
  47. Cynis H, Rahfeld JU, Stephan A, Kehlen A, Koch B, Wermann M, Demuth HU, Schilling S. Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. J Mol Biol. 2008;379(5):966-980. doi: 10.1016/j.jmb.2008.03.078
  48. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol. 2000;166(2):235-245.
  49. Dando PM, Fortunato M, Strand GB, Smith TS, Barrett AJ. Pyroglutamyl-peptidase I: cloning, sequencing, and characterisation of the recombinant human enzyme. Protein Expr Purif. 2003;28(1):111-119.
  50. Torshin IYu. Bioinformatics in the post-genomic era: physiology and medicine. Nova Biomedical Books, NY, USA. 2007.
  51. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35:521-526.
  52. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39-45.
  53. Park SK, Jung IC, Lee WK, Lee YS, Park HK, Go HJ, Kim K, Lim NK, Hong JT, Ly SY, Rho SS. A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food. 2011;14(4):334-343. doi: 10.1089/jmf.2009.1374
  54. Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol. 2008;77(2):113-122.
  55. Kakuda T, Nozawa A, Sugimoto A, Niino H. Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem. 2002;66(12):2683-2686.
  56. Petroff OA, Hyder F, Collins T, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia. 1999;40(7):958-964.
  57. Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder M, Triplett AA, Schurig V, Finnell RH. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia. 2003;44(10):1280-1288.
  58. Nishizaki T, Matsumura T. The aniracetam metabolite 2-pyrrolidinone induces a long-term enhancement in AMPA receptor responses via a CaMKII pathway. Brain Res Mol Brain Res. 2002;98(1-2):130-134.
  59. Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(suppl):7-88.
  60. Spignoli G, Magnani M, Giovannini MG, Pepeu G. Effect of pyroglutamic acid stereoisomers on ECS and scopolamine-induced memory disruption and brain acetylcholine levels in the rat. Pharmacol Res Commun. 1987;19(12):901-912.
  61. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 1994;19(2):180-222.
  62. Jordaan B, Oliver DW, Dormehl IC, Hugo N. Cerebral blood flow effects of piracetam, pentifylline, and nicotinic acid in the baboon model compared with the known effect of acetazolamide. Arzneimittelforschun. 1996;46(9):844-847.
  63. Grau M, Montero JL, Balasch J. Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat. Gen Pharmacol. 1987;18(2):205-211.
  64. Nickolson VJ, Wolthuis OL. Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine. Biochem Pharmacol. 1976;25(20):2241-2244.
  65. Barone D, Spignoli G. Investigations on the binding properties of the nootropic agent pyroglutamic acid. Drugs Exp Clin Res. 1990;16(2):85-99.
  66. Antonelli T, Carla V, Lambertini L, Moroni F, Bianchi C. Pyroglutamic acid administration modifies the electrocorticogram and increases the release of acetylcholine and GABA from the guinea-pig cerebral cortex. Pharmacol Res Commun. 1984;16(2):189-197.
  67. Raiyuchkin VA. Experience enhance the effectiveness of antidepressant therapy with Magne В6. Materiali nauchno-prakticheskoiy konferencii. М. 1998;383-385. (In Russ).
  68. Dwoskin LP, Teng L, Buxton ST, Crooks PA. (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther. 1999;288(3):905-911.
  69. Anderson DJ, Arneric SP. Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. Eur J Pharmacol. 1994;253(3):261-267.
  70. Briggs CA, McKenna DG. Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology. 1998;37(9):1095-1102.
  71. Buccafusco JJ, Shuster LC, Terry AV Jr. Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine. Neurosci Lett. 2007;413(1):68-71.
  72. Buccafusco JJ, Terry AV Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol. 2009;78(7):852-862. doi: 10.1016/j.bcp.2009.06.102
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.